ArticleInternational journal of nanomedicine2012
Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 80 citations in OpenAlex.
- Assessment of the Photosynthetic Response of Potato Plants Inoculated withPlants (Basel, Switzerland) · 2025Article
- Improved Biopharmaceutical Performance of Coenzyme Q10 Through Solid Lipid Nanoparticles for Enhanced Brain Delivery.Scientifica · 2025Article
- Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Surface Functionalized Lipid Nanoparticles in Promoting Therapeutic Outcomes: An Insight View of the Dynamic Drug Delivery System.Current drug targets · 2024Review
- Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs.Pharmaceutics · 2023Article
- Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.Pathogens (Basel, Switzerland) · 2023Review
- Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.Acta pharmaceutica Sinica. B · 2021Review
- Polymeric nano-vesiclesRSC advances · 2020Article
- Nanoparticles for antiparasitic drug delivery.Drug delivery · 2019Review
- Nanoparticle Delivery Systems in the Treatment of Diabetes Complications.Molecules (Basel, Switzerland) · 2019Review
- Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles.International journal of nanomedicine · 2019Article
- Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape.International journal of nanomedicine · 2018Review
- Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers.Journal of food and drug analysis · 2017Review
- Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes.Journal of nanobiotechnology · 2015Review
- Solid Lipid Nanoparticles: A Potential Multifunctional Approach towards Rheumatoid Arthritis Theranostics.Molecules (Basel, Switzerland) · 2015Article
- Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery.Drug design, development and therapy · 2015Review
- A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.Cancer prevention research (Philadelphia, Pa.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to design and characterize solid lipid nanoparticles (SLNs) modified with stearic acid-octaarginine (SA-R₈) as carriers for oral administration of insulin (SA-R₈-Ins-SLNs). The SLNs were prepared by spontaneous emulsion solvent diffusion methods. The mean particle size, zeta potential, drug loading, and encapsulation efficiency of the SA-R₈-Ins-SLNs were 162 nm, 29.87 mV, 3.19%, and 76.54%, respectively. The zeta potential of the SLNs changed dramatically, from -32.13 mV to 29.87 mV, by binding the positively charged SA-R₈. Morphological studies of SA-R₈-Ins-SLNs using transmission electron microscopy showed that they were spherical. In vitro, a degradation experiment by enzymes showed that SLNs and SA-R₈ could partially protect insulin from proteolysis. Compared to the insulin solution, the SA-R₈-Ins-SLNs increased the Caco-2 cell's internalization by up to 18.44 times. In the in vivo studies, a significant hypoglycemic effect in diabetic rats over controls was obtained, with a SA-R₈-Ins-SLN pharmacological availability value of 13.86 ± 0.79. These results demonstrate that SA-R₈-modified SLNs promote the oral absorption of insulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.